Literature DB >> 19358442

Radiofrequency ablation of primary and metastatic lung cancers.

Bradley B Pua1, Stephen B Solomon.   

Abstract

Radiofrequency ablation is an accepted method of therapy for unresectable liver cancer. Most recently, interest in using this technology for treatment of primary and metastatic lung tumors has increased. Early animal studies have led to numerous human trials that suggest that radiofrequency ablation can play a major role in treatment of both early-stage primary lung cancer and metastatic lesions. Technical aspects of this therapy as well as areas of further research are discussed.

Entities:  

Mesh:

Year:  2009        PMID: 19358442     DOI: 10.1053/j.sult.2008.12.001

Source DB:  PubMed          Journal:  Semin Ultrasound CT MR        ISSN: 0887-2171            Impact factor:   1.875


  6 in total

1.  Microwave ablation treatment of liver cancer with 2,450-MHz cooled-shaft antenna: an experimental and clinical study.

Authors:  Dechao Jiao; Linxue Qian; Yanling Zhang; Fujun Zhang; Chuanxing Li; Zilin Huang; Liang Zhang; Weidong Zhang; Peihong Wu; Xinwei Han; Guangfeng Duan; Jianjun Han
Journal:  J Cancer Res Clin Oncol       Date:  2010-02-20       Impact factor: 4.553

2.  A phase II study of radiofrequency ablation therapy for thoracic malignancies with evaluation by FDG-PET.

Authors:  Mitsunori Higuchi; Hiroshi Honjo; Takeshi Shigihara; Fumio Shishido; Hiroyuki Suzuki; Mitsukazu Gotoh
Journal:  J Cancer Res Clin Oncol       Date:  2014-06-21       Impact factor: 4.553

Review 3.  The role of percutaneous image-guided ablation for lung tumors.

Authors:  Elena N Petre; Stephen B Solomon; Constantinos T Sofocleous
Journal:  Radiol Med       Date:  2014-07-01       Impact factor: 3.469

4.  Radiofrequency versus microwave ablation for treatment of the lung tumours: LUMIRA (lung microwave radiofrequency) randomized trial.

Authors:  M Macchi; M P Belfiore; C Floridi; N Serra; G Belfiore; L Carmignani; R F Grasso; E Mazza; C Pusceddu; L Brunese; G Carrafiello
Journal:  Med Oncol       Date:  2017-04-18       Impact factor: 3.064

5.  [Radiofrequency ablation for the treatment of lung neoplasms: a retrospective study of 329 cases].

Authors:  Qiang Lu; Xiaofei Li; Yong Han; Zhipei Zhang; Xiaolong Yan; Lijun Huang
Journal:  Zhongguo Fei Ai Za Zhi       Date:  2011-11

6.  Ki 67 is an independent predictive biomarker of cancer specific and local recurrence-free survival after lung tumor ablation.

Authors:  Constantinos T Sofocleous; Sandeep K Garg; Perry Cohen; Elena N Petre; Mithat Gonen; Joseph P Erinjeri; Robert J Downey; William D Travis; Stephen B Solomon
Journal:  Ann Surg Oncol       Date:  2013-07-30       Impact factor: 4.339

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.